

# Major Depressive Disorder Treatment Market Shows Increasing Demand Due to High Adoption | Allergan, Alkermes, Lundbeck,

SEATTLE, WASHINGTON, UNITED STATES, March 10, 2022 /EINPresswire.com/ -- Coherent Market Insights published a business research report on Major Depressive Disorder Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2022–2028. Major Depressive Disorder Treatment Market with 150+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The information is gathered based on modern floats and requests

identified with the administrations and items.

**GLOBAL MAJOR DEPRESSIVE DISORDER** MARKET ANALYSIS MARKET TAXONOMY • By Drug Type • Serotonin Modulators ◆ Selective Serotonin Reuptake Inhibitors (SSRIS) ◆ Norepinephrine-Serotonin • Lexapro (Escitalopram) • Tricyclics and Tetracyclics **KEY PLAYERS ▶** Antipsychotics ◆ Serotonin Norepinephrine Reuptake Inhibitor • Abilify (Aripiprazole) • Cymbalta (Duloxetine) ◆ Seroquel XR (Quetiapine XR) • Effexor (Venlafaxine) ◆ Rexulti (Brexpiprazole) • Fetzima (Levomilnacipran) **▶** Neuromodulators Savella (Milnacipran) Johnson & Johnson • Takeda Pharmaceu ▶Stem Cell Therapy Pristiq (Desvenlafaxine) Pfizer, Inc. Major Depressive Disorder Treatment Market

Major Depressive Disorder (MDD) Treatment Market is poised to showcase impressive growth prospects on account of increasing routine check-ups for mental health

#### Overview

Major Depressive Disorder (MDD) is a debilitating mental illness with various forms. It can impact a person's everyday life, causing them to feel hopeless. Symptoms include a loss of interest in once-pleasing activities, a general sense of melancholy, and increased anxiety. Treatment for MDD often involves psychotherapy, which helps people understand the causes of their symptoms and find ways to address them. Often, psychotherapy can be used as a complement to conventional medicine, but it cannot replace medical treatment. A doctor can diagnose this condition based on reported experiences and a mental status examination. There is no laboratory test to diagnose MDD, but certain tests are performed to rule out physical conditions that are likely to cause similar symptoms.

## Competitive Landscape

Major companies contributing to the global major depressive disorder (MDD) treatment market include Pfizer, Inc., Johnson & Johnson, Lundbeck, Alkermes, Allergan, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Sanofi S.A., GlaxoSmithKline, Merck & Co., and AstraZeneca PLC.

#### **Drivers**

Increasing number of routine check-ups in the wake of rising awareness over depressive disorders is expected to augment the growth of the major depressive disorder (MDD) treatment market during the forecast period.

Moreover, a robust pipeline of final-stage drugs and therapies to manage this disorder is expected to further cushion the growth of the major depressive disorder (MDD) treatment market over the forecast period.

The Epitome of the COVID-19 Aftermath

The global major depressive disorder (MDD) treatment market witnessed a steep increase in business during the emergence and resurgence of the COVID-19 virus along with its variants. The crisis-fueled restrictions on outdoor activities, combined with self-isolation and social distancing measures, have majorly increased the caseload of depression. On top of that, the increasing unemployment rate is favoring the expansion of the market.

## **Key Takeaways**

- The major depressive disorder (MDD) treatment market is owing to the rising cases of depression, increased awareness of mental health issues, and the growing approval rate of novel therapies. For instance, in August 2021, Nexstim PLC received approval for its Navigated Brain Therapy (NBT®) system from the U.S. Food and Drug Administration (FDA) to market and commercialize distribution of its major depressive disorder (MDD) treatment in the U.S.
- By expanding the horizons, the North American region is augmenting the scope of the global major depressive disorder (MDD) treatment market on the heels of increasing cases of depression as a result of hectic lifestyles and an accelerated approval pathway for novel therapies.
- In parallel, the Asia Pacific region is undergoing rapid expansion in the global major depressive

disorder (MDD) treatment market on account of increased spending on mental healthcare and a rising senescent population.

0000000 0000 000000 000000 0000 0000 0

### About US:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Mr. Shah
Coherent Market Insights Pvt. Ltd.
+1 206-701-6702
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
Other

This press release can be viewed online at: https://www.einpresswire.com/article/565195792

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.